Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Other Accumulated Expenses (2016 - 2025)

Regenxbio (RGNX) has 12 years of Other Accumulated Expenses data on record, last reported at $757000.0 in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 16.64% year-over-year to $757000.0; the TTM value through Dec 2025 reached $757000.0, up 16.64%, while the annual FY2025 figure was $757000.0, 16.64% up from the prior year.
  • Other Accumulated Expenses reached $757000.0 in Q4 2025 per RGNX's latest filing, down from $929000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $999000.0 in Q1 2023 and bottomed at $122000.0 in Q1 2021.
  • Average Other Accumulated Expenses over 5 years is $697500.0, with a median of $748000.0 recorded in 2022.
  • The widest YoY moves for Other Accumulated Expenses: up 363.44% in 2021, down 58.64% in 2021.
  • A 5-year view of Other Accumulated Expenses shows it stood at $744000.0 in 2021, then grew by 0.27% to $746000.0 in 2022, then crashed by 38.61% to $458000.0 in 2023, then soared by 41.7% to $649000.0 in 2024, then grew by 16.64% to $757000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $757000.0 in Q4 2025, $929000.0 in Q3 2025, and $736000.0 in Q2 2025.